IOL Chemicals and Pharmaceuticals Limited
Momentum (95/100) does the heavy lifting; quality (54/100) is the drag.
Buy zoneStocksWizard rates IOL Chemicals and Pharmaceuticals Limited a Strong Buy, scoring 76/100 on our blended model. At ₹194.31 it trades below our blended DCF and relative-multiples fair value of ₹224.26, about 15% upside to that estimate — we read it as undervalued by 15%. On 28.0x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 9% below its 52-week high of ₹213.04 and 185% above the low of ₹68.15. Financial health scores 96/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹150 implies about 23% downside across 1 analysts. It clears 8 of 13 investability checks, with durability 54, valuation 80 and momentum 95 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹179.41.
Analyst views
1-year price
EOD · 2026-09-1452-week range
-8.79% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy76Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 7.9%
- Pass: Low debt (D/E < 0.5): 0.08x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 17%
- Pass: Earnings growing: 70%
- Fail: Net margin ≥ 10%: 5.9%
- Pass: Current ratio > 1.5: 1.78
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.83
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter67.0%
- Institutions1.3%
- Public & other31.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 4.83.
Opportunities
- Earnings growing (70% YoY).
- Revenue growing (17% YoY).
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Low return on equity (7.9%).
About IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals manufactures pharmaceutical and chemical products for domestic and international markets across two segments. Its Chemical segment produces ethyl acetate, isobutyl benzene, acetyl chloride, monochloroacetic acid, and acetic anhydride for use in food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries.
IOL Chemicals and Pharmaceuticals Limited — frequently asked questions
Is IOL Chemicals and Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates IOL Chemicals and Pharmaceuticals Limited (IOLCP) a Strong Buy, based on a blended score of 76/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is IOL Chemicals and Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates IOL Chemicals and Pharmaceuticals Limited's fair value at about ₹224.26, versus a current price of ₹194.31 — roughly 15% upside. On that basis the stock looks undervalued by 15%.
Is IOL Chemicals and Pharmaceuticals Limited financially healthy?
IOL Chemicals and Pharmaceuticals Limited scores 96/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has IOL Chemicals and Pharmaceuticals Limited's share price performed?
IOL Chemicals and Pharmaceuticals Limited is up 54% over three months, and last traded at ₹194.31. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.